NASDAQ:CUR - Neuralstem Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Neuralstem, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $0.63 +0.01 (+1.61 %) (As of 03/29/2020 05:15 AM ET) Add Compare Today's Range$0.58Now: $0.63▼$0.6350-Day Range$0.59MA: $0.85▼$1.1052-Week Range$1.10Now: $0.63▼$13.78Volume163,977 shsAverage Volume1.98 million shsMarket Capitalization$1.32 millionP/E RatioN/ADividend YieldN/ABeta1.81 ProfileAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Neuralstem, Inc., a clinical stage biopharmaceutical company, focuses on the research and development of nervous system therapies based on its proprietary human neuronal stem cells and small molecule compounds. The company's stem cell based technology enables the isolation and expansion of human neural stem cells from various areas of the developing human brain and spinal cord enabling the generation of physiologically relevant human neurons of various types. Its lead product candidate is NSI-189, a chemical entity, which has been completed Phase II clinical trial for the treatment of major depressive disorder, as well as is in preclinical study for the treatment-refractory depression, Angelman Syndrome, Alzheimer's disease, ischemic stroke, diabetic neuropathy, irradiation-induced cognitive deficit, and long-term potentiation enhancement. The company also develops NSI-566, which has completed Phase II clinical trial for treating amyotrophic lateral sclerosis disease; Phase II clinical trial for the treatment of chronic ischemic stroke; and Phase I clinical trials for the treatment of chronic spinal cord injury, as well as is in preclinical study for the traumatic brain injury. In addition, it develops NSI-532, which is in preclinical study for treatment of Alzheimer's disease; and NSI-777 that is in preclinical study for treatment of human demyelinating diseases. Neuralstem, Inc. was founded in 1996 and is headquartered in Germantown, Maryland.Read More Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:CUR Previous Symbol CUSIPN/A CIK1357459 Webhttp://www.neuralstem.com/ Phone301-366-4841Debt Debt-to-Equity RatioN/A Current Ratio2.53 Quick Ratio2.53Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$260,000.00 Price / Sales5.09 Cash FlowN/A Price / Cash FlowN/A Book Value$6.64 per share Price / Book0.09Profitability EPS (Most Recent Fiscal Year)N/A Net Income$-4,930,000.00 Net Margins-39,417.64% Return on Equity-170.51% Return on Assets-110.16%Miscellaneous Employees6 Outstanding Shares2,100,000Market Cap$1.32 million Next Earnings DateN/A OptionableOptionable Receive CUR News and Ratings via Email Sign-up to receive the latest news and ratings for CUR and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:CUR Rates by TradingView Neuralstem (NASDAQ:CUR) Frequently Asked Questions How has Neuralstem's stock been impacted by COVID-19 (Coronavirus)? Neuralstem's stock was trading at $0.7516 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, CUR stock has decreased by 16.2% and is now trading at $0.6298. View which stocks have been mosted impacted by Coronavirus. How were Neuralstem's earnings last quarter? Neuralstem, Inc. (NASDAQ:CUR) posted its quarterly earnings data on Wednesday, August, 14th. The company reported ($1.45) earnings per share for the quarter. The company had revenue of $0.01 million for the quarter. Neuralstem had a negative net margin of 39,417.64% and a negative return on equity of 170.51%. View Neuralstem's earnings history. When did Neuralstem's stock split? How did Neuralstem's stock split work? Neuralstem's stock reverse split on Thursday, July 18th 2019. The 1-20 reverse split was announced on Tuesday, July 16th 2019. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, July 17th 2019. An investor that had 100 shares of Neuralstem stock prior to the reverse split would have 5 shares after the split. Has Neuralstem been receiving favorable news coverage? News coverage about CUR stock has been trending somewhat positive on Sunday, InfoTrie Sentiment Analysis reports. InfoTrie ranks the sentiment of media coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Neuralstem earned a news sentiment score of 1.2 on InfoTrie's scale. They also gave news stories about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the near future. View the latest news aboutNeuralstem. Who are some of Neuralstem's key competitors? Some companies that are related to Neuralstem include Vitro Diagnostics (VODG), Gene Biotherapeutics (CRXM), Innate Pharma (IPHA), Mymetics (MYMX) and Omni Bio Pharmaceutical (OMBP). What other stocks do shareholders of Neuralstem own? Based on aggregate information from My MarketBeat watchlists, some companies that other Neuralstem investors own include XOMA (XOMA), MannKind (MNKD), Cytokinetics (CYTK), Turkcell Iletisim Hizmetleri A.S. (TKC), Idera Pharmaceuticals (IDRA), NovaBay Pharmaceuticals (NBY), TransEnterix (TRXC), SLS International (SLS), ACADIA Pharmaceuticals (ACAD) and Caladrius Biosciences (CLBS). Who are Neuralstem's key executives? Neuralstem's management team includes the following people: Dr. Kenneth C. Carter, Exec. Chairman, CEO & Principal Financial Officer (Age 59)Dr. Karl Y. Johe, Co-Founder (Age 59)Dr. Thomas G. Hazel Ph.D., Sr. VP of ResearchDr. David P. Recker, Chief Medical Officer (Age 61) What is Neuralstem's stock symbol? Neuralstem trades on the NASDAQ under the ticker symbol "CUR." How do I buy shares of Neuralstem? Shares of CUR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Neuralstem's stock price today? One share of CUR stock can currently be purchased for approximately $0.63. How big of a company is Neuralstem? Neuralstem has a market capitalization of $1.32 million and generates $260,000.00 in revenue each year. Neuralstem employs 6 workers across the globe. View additional information about Neuralstem. What is Neuralstem's official website? The official website for Neuralstem is http://www.neuralstem.com/. How can I contact Neuralstem? Neuralstem's mailing address is 20271 Goldenrod Lane, Germantown MD, 20876. The company can be reached via phone at 301-366-4841 or via email at [email protected] MarketBeat Community Rating for Neuralstem (NASDAQ CUR)Community Ranking: 2.5 out of 5 ( )Outperform Votes: 278 (Vote Outperform)Underperform Votes: 273 (Vote Underperform)Total Votes: 551MarketBeat's community ratings are surveys of what our community members think about Neuralstem and other stocks. Vote "Outperform" if you believe CUR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CUR will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 3/29/2020 by MarketBeat.com StaffFeatured Article: How do analysts define an oversold condition?
